Wisteria floribunda agglutinin‐positive mucin 1 is a sensitive biliary marker for human cholangiocarcinoma

• Published in: Hepatology (Baltimore, Md.) Vol. 52; no. 1; pp. 174 - 182
• Main Authors: Matsuda, Atsushi, Kuno, Atsushi, Kawamoto, Toru, Matsuzaki, Hideki, Irimura, Tatsuro, Ikehara, Yuzuru, Zen, Yoh, Nakanuma, Yasuni, Yamamoto, Masakazu, Ohkohchi, Nobuhiro, Shoda, Junichi, Hirabayashi, Jun, Narimatsu, Hisashi
• Format: Journal Article
• Language: English
• Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.07.2010; Wiley; Wiley Subscription Services, Inc
• Subjects: Antibodies, Monoclonal - immunology; Bile; Bile - chemistry; Bile Duct Neoplasms - diagnosis; Bile Ducts, Intrahepatic; Biological and medical sciences; Biomarkers, Tumor - analysis; Cholangiocarcinoma - diagnosis; Enzyme-Linked Immunosorbent Assay; Gastroenterology. Liver. Pancreas. Abdomen; Hepatology; Humans; Liver. Biliary tract. Portal circulation. Exocrine pancreas; Medical sciences; Mucin-1 - analysis; Plant Lectins - chemistry; Plant Lectins - immunology; Protein Array Analysis; Receptors, N-Acetylglucosamine - chemistry; Receptors, N-Acetylglucosamine - immunology; Staining and Labeling; Tumors; Wisteria floribunda; Human; Biliary tract; Mucin; Malignant cholangioma; Agglutinin; Gastroenterology; Digestive diseases; Hepatic disease; Malignant tumor; Biliary tract disease; Cancer
• ISSN: 0270-9139; 1527-3350
• DOI: 10.1002/hep.23654

Cholangiocarcinoma (CC) is an aggressive malignant tumor for which useful markers are not presently available for early and precise diagnosis. The aim of this study was therefore to identify a high‐performance diagnostic marker with a special focus on glyco‐alteration of glycoproteins. In the course of study, we found that Wisteria floribunda agglutinin (WFA) is the best probe to differentiate intrahepatic cholangiocarcinoma (ICC) lesions from normal bile duct epithelia (BDE) (P < 0.0001). The subsequent histochemical study confirmed ICC‐specific WFA staining on 165 tissue specimens. On the other hand, the WFA staining was shown to be closely associated with that of MY.1E12 established previously against sialylated mucin 1 (MUC1) by double‐staining experiments. Moreover, glyco‐alteration of MUC1 could be verified by western blotting of WFA‐captured bile samples from patients with CC patients. Thus, we attempted to construct an enzyme‐linked immunosorbent assay system for more convenient CC diagnosis, where WFA‐coated plates, the specific monoclonal antibody MY.1E12, and the bile specimens from CC including ICC (n = 30) and benign diseases (n = 38) were combined. As a result, CC was clearly distinguished from benign diseases with statistical scores (sensitivity = 90.0%, specificity = 76.3%, and area under the curve = 0.85). As a particular note, the obtained sensitivity is the highest score among those having been so far reported. Conclusion: Our approach focusing significant glyco‐alteration of a particular glycoprotein yielded a novel diagnostic system for CC with satisfactory clinical scores. HEPATOLOGY 2010